Collegium Pharmaceutical Inc (NASDAQ:COLL) had a decrease of its shorted shares by 8.61%. It was issued in March by FINRA the 2.62M shorted shares on COLL. The 2.87 million previous shares are down with 8.61%. Former COLL’s position will need 7 days to restore. It has 403,100 average volume.

COLL is touching $15.8 during the last trading session, after decreased 7.06%.Collegium Pharmaceutical, Inc. is downtrending after having declined 24.57% since March 23, 2018. COLL has 550,131 volume or 22.48% up from normal. COLL underperformed the S&P 500 by 28.94%.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases.The company has $527.28 million market cap. It offers Xtampza, an oral formulation of oxycodone, for the management of pain.Last it reported negative earnings. The firm also develops Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Ratings Coverage

A total of 3 analysts rate Collegium Pharmaceutical (NASDAQ:COLL) as follows: 3 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:COLL) has 6 ratings reports on Mar 23, 2019 according to StockzIntelligence. On Friday, March 8 the rating was maintained by Cantor Fitzgerald with “Buy”. On Friday, March 15 Cantor Fitzgerald maintained Collegium Pharmaceutical, Inc. (NASDAQ:COLL) with “Buy” rating. On Monday, March 4 the stock has “Buy” rating by H.C. Wainwright. On Friday, March 22 the rating was maintained by Cantor Fitzgerald with “Buy”. On Tuesday, March 19 SunTrust initiated Collegium Pharmaceutical, Inc. (NASDAQ:COLL) rating. SunTrust has “Buy” rating and $22 target. On Friday, February 22 Cantor Fitzgerald maintained the shares of COLL in report with “Buy” rating.

For more Collegium Pharmaceutical, Inc. (NASDAQ:COLL) news posted briefly go to: Prnewswire.com, Benzinga.com, Seekingalpha.com, Seekingalpha.com or Globenewswire.com. The titles are as follows: “Correvio Announces Presentation Of Brinavess® Data At The American College Of Cardiology 2019 Annual Meeting – PRNewswire” posted on March 20, 2019, “The Week Ahead In Biotech (Feb. 24-March 2): Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs – Benzinga” on February 22, 2019, “Axsome Therapeutics leads healthcare gainers; La Jolla Pharmaceutical and ContraFect among losers – Seeking Alpha” with a publish date: January 07, 2019, “Collegium: Soft Reaction To Softer Growth – Seeking Alpha” and the last “Collegium Reports Third Quarter Financial Results Nasdaq:COLL – GlobeNewswire” with publication date: November 08, 2018.